BiotechTube

Temozolomide and Bevacizumab

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma

Trial Timeline

Apr 1, 2008 → Dec 1, 2010

NCT ID
NCT00660621

About Temozolomide and Bevacizumab

Temozolomide and Bevacizumab is a phase 2 stage product being developed by Eisai for Glioma. The current trial status is unknown. This product is registered under clinical trial identifier NCT00660621. Target conditions include Glioma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00660621Phase 2UNKNOWN

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
28
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
LY2157299 + LomustineEli LillyPhase 1
33
DS-1001bDaiichi SankyoPhase 2
52
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
41
TemozolomideEisaiPhase 2
52
Gliadel Wafer + TemozolomideEisaiPhase 2
52
Palonosetron (PALO)EisaiPhase 2
52
Gliadel/Avastin/CPT-11EisaiPhase 2
52
Lenvatinib + BevacizumabEisaiPhase 2
52
Granisetron + OndansetronKyowa KirinPhase 2
52
Binimetinib 15 MGOno PharmaceuticalPhase 2
52
EnzastaurinEli LillyPhase 2
52
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
41
Abemaciclib + TemozolomideEli LillyPhase 2
52
DSP-0390Sumitomo PharmaPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85